Meeting
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
Authors
Gang Hua
Department of Cardiothoracic Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China
Gang Hua , Xiaoxi Chen , Ruoying Yu , Hua Bao , Xue Wu , Yang Shao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3011)
DOI
10.1200/JCO.2021.39.15_suppl.3011
Abstract #
3011
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2019 ASCO Annual Meeting
Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.
First Author: Ibiayi Dagogo-Jack
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge